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Inflammatory cytokines such as TNF may play a role in the
pathogenesis of common metabolic disorders, including hy-
perandrogenism and the polycystic ovary syndrome (PCOS).
The TNF receptor 2 mediates most of the metabolic effects of
TNF. In the present study, we have evaluated serum soluble
TNF receptor 2 levels, and several common polymorphisms in
the TNF receptor 2 gene (TNFRSF1B), in women presenting
with PCOS or hyperandrogenic disorders. Initial studies in-
cluded 103 hyperandrogenic patients (42 presenting with
PCOS) and 36 controls from Spain. The 196R alleles of the
M196R (676 T3G) variant in exon 6 of TNFRSF1B, which is in
linkage disequilibrium with a CA-repeat microsatellite poly-
morphism in intron 4 of TNFRSF1B, tended to be more fre-
quent in hyperandrogenic patients than in controls (P 
0.056), reaching statistical significance when the analysis was
restricted to include only PCOS patients (P < 0.03). Extended
analysis including another 11 hyperandrogenic patients from
Spain and 64 patients and 29 controls from Italy confirmed the
association between 196R alleles of the M196R variant and
hyperandrogenic disorders (P < 0.05), which was maintained
when restricting the analysis to PCOS patients (P < 0.02). On
the contrary, the 3-untranslated region (exon 10) variants
1663 G3A, 1668 T3G, and 1690 T3C were not associated with
hyperandrogenism. The soluble TNF receptor 2 levels were
not different between patients and controls but were in-
creased in obese subjects, compared with lean individuals,
and were affected by the interaction between the 1663 G3A
and 1668 T3G variants in the 3-untranslated region of
TNFRSF1B. The TNFRSF1B genotype did not influence any
clinical or biochemical variable related to hyperandrogenism
or insulin sensitivity and was not associated with obesity,
both in hyperandrogenic patients and healthy controls con-
sidered separately. In conclusion, the M196R (676 T3G) vari-
ant in exon 6 of TNFRSF1B is associated with hyperandro-
genism and PCOS, further suggesting a role for inflammatory
cytokines in the pathogenesis of these disorders. (J Clin En-
docrinol Metab 87: 3977–3983, 2002)
INFLAMMATORY CYTOKINES SUCH as TNF- play arole in the pathogenesis of metabolic diseases, such as
obesity and insulin resistance-related disorders (1). TNF-
participates in obesity-related systemic insulin resistance by
inhibiting the insulin receptor tyrosine kinase in muscle and
fat, which are the two tissues mainly responsible for insulin-
stimulated glucose uptake (2, 3). Hyperandrogenism and the
polycystic ovary syndrome (PCOS) are common disorders in
reproductive-aged women (4, 5) and are also included among
the constellation of consequences of insulin resistance (6).
We have recently described that the TNF- axis may also
influence the pathogenesis of hyperandrogenism, indepen-
dently from insulin resistance and obesity (7). Serum TNF-
levels were mildly increased in hyperandrogenic patients,
especially in those with idiopathic hirsutism (7). Also, when
considering patients and controls as a whole, carriers of the
A allele of the common 308G3A single nucleotide poly-
morphism in the promoter of the TNF- gene presented with
increased serum androgen levels (7). However, 308A al-
leles were equally distributed among patients and controls,
suggesting that this variant is only a contributing factor to the
pathogenesis of androgen excess, instead of being a major
etiology for this disorder (7).
TNF actions are mainly mediated by type 1 (p55 or p60,
TNFR1) and type 2 (p75 or p80, TNFR2) TNF receptors
(TNFRs). The mRNAs of both receptors are up-regulated
in adipose tissue of obese women, correlating with body
mass index (BMI) and several indirect markers of insulin
resistance (8, 9). Studies in genetically obese animals lack-
ing these receptors have shown that TNFR1 is the major
mediator of the TNF induced insulin resistance and
TNFR2 might potentiate this effect (10). On activation of
the TNF system soluble forms of TNFRs are shed into the
circulation and may be measured by specific immunoas-
Abbreviations: A, 4-Androstenedione; BMI, body mass index; CI,
confidence interval; DHEAS, dehydroepiandrosterone-sulfate; FIRI,
fasting insulin resistance index; PCOS, polycystic ovary syndrome;
sTNFR2, soluble TNF receptor 2; TNFR, TNF receptor; UTR, untrans-
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says. The circulating levels of soluble TNFR2 (sTNFR2),
but not those of soluble TNFR1, are increased in obese
subjects, correlating with indexes of insulin resistance and
serum lipid variables (11–14). However, most of these
correlations seem to be derived from the stronger corre-
lation with BMI because serum sTNFR2 levels are mainly
determined by adiposity and genetic factors (15).
Variability at the gene encoding TNFR2 (TNFRSF1B,
located at chromosome 1p36.2), influences sTNFR2 levels
(16, 17) and has been proposed to play a role in the patho-
genesis of several metabolic disorders, including familial
combined hyperlipidemia (17), hypertension (16), obesity
and insulin resistance (18), and coronary artery dis
zhyease (19).
In the present study, we evaluated sTNFR2 levels and
several common polymorphisms in TNFRSF1B in a large
series of hyperandrogenic patients and healthy controls from
Spain and Italy to further explore the role of the TNF system
in the pathogenesis of hyperandrogenism and PCOS.
Materials and Methods
Subjects
Initial studies included 103 hyperandrogenic patients from Spain
recruited prospectively, who presented with hirsutism and/or hyperan-
drogenic anovulation. As stated above, because our previous finding of
increased serum TNF levels in hyperandrogenic women was not re-
stricted to PCOS patients (7), we decided to study the possible role of
TNFR2 in women presenting with a larger spectrum of hyperandrogenic
disorders, focusing secondarily on the subset of women presenting with
PCOS. The control group of 36 nonhyperandrogenic women included
lean female volunteers and patients attending the clinical practice of one
of the authors (H.F.E.-M.) for the treatment of obesity. None of the
controls had signs or symptoms of hyperandrogenism, menstrual dys-
function, or history of infertility.
Hirsutism, as defined by a modified Ferriman-Gallwey score (20) of
8 or more, was present in 98 of the patients, with a mean score of 15.2
(sd) 5.3. PCOS, defined by clinical and/or biochemical hyperandro-
genism, oligomenorrhea, and exclusion of other etiologies (21), was
present in 42 patients, including the 5 nonhirsute patients. Forty-four
patients had hyperandrogenemic hirsutism, defined by hirsutism, in-
creased serum androgen levels, and regular menses, and 17 patients
presented with idiopathic hirsutism, defined by hirsutism, normal an-
drogen levels, and regular menstrual cycles.
Because the initial study suggested an association of hyperandro-
genism with one of the genomic variants in TNFRSF1B, the study was
extended to increase the sample size and the statistical power with the
inclusion of another 11 consecutive Spanish patients (eight presenting
with PCOS, two with hyperandrogenemic hirsutism, and one with id-
iopathic hirsutism) as well as 64 hyperandrogenic patients recruited
prospectively (58 presenting with PCOS, 2 with hyperandrogenemic
hirsutism, and 4 with idiopathic hirsutism) and 29 healthy controls from
northeastern Italy.
None of the patients had features of Cushing’s disease or drug-
induced hirsutism. Hyperprolactinemia and congenital adrenal hyper-
plasia were ruled out because all the patients presented with basal serum
PRL levels less than 24 g/liter and ACTH-stimulated 17-hydroxypro-
gesterone levels less than 30 nmol/liter (22). All the controls and patients
had blood pressure less than 140/90 mm Hg and fasting glucose levels
less than 6.1 mmol/liter.
The patients and controls had not taken hormonal medications, in-
cluding oral contraceptives, for the last 6 months. All the subjects were
Caucasian. Data from some of the Spanish patients and controls, re-
garding different aspects of the pathophysiology of hirsutism, have been
previously published (7, 23–27).
The ethics committees of the Hospital Ramo´n y Cajal and the Uni-
versity of Verona approved the study, and informed consent was ob-
tained from each patient and control.
Study protocol and hormone profiles
Studies were performed during the midfollicular phase of the men-
strual cycle or during amenorrhea, after excluding pregnancy by proper
testing. In all the subjects, with the exception of 11 Italian controls,
fasting basal serum samples were obtained for the measurement of total
T, SHBG, 4-androstenedione (A), dehydroepiandrosterone-sulfate
(DHEAS), glucose, and insulin. Samples were immediately centrifuged,
and serum was separated and frozen at 20 C until assayed. The sam-
ples from the 103 patients and 36 controls from Spain initially studied
were also assayed for serum sTNFR2.
Serum sTNFR2 levels were measured by ELISA kit (Quantikine
human sTNF RII kit, R&D Systems, Minneapolis, MN) with a lower
limit of detection of less than 1.0 pg/ml, and mean intra- and inter-
assay coefficients of variation of 2.2% and 4.1%, respectively. Serum
glucose was measured by the glucose oxidase method. Serum insulin,
A, DHEAS, and SHBG were measured by commercial immunoassays
(Diagnostic Products, Los Angeles, CA). Intra- and interassay coef-
ficients of variation were 4.3% and 5.4% for insulin, 5.7% and 8.4%
for A, 8.2% and 12.0% for DHEAS, and 6.5% and 8.7% for SHBG. Total
T was assayed by direct RIA using commercial assays: Spectria Total
Testosterone (Orion Diagnostica, Espoo, Finland) was used for Span-
ish samples, with intra- and interassay coefficients of variation of
5.3% and 5.4%, and Coat-A-Count Total Testosterone (Diagnostic
Products) was used for Italian samples, with intra- and interassay
coefficients of variation of 6.5% and 8.5%. The linear regression anal-
ysis of the two methods was established by measuring 12 samples,
yielding the following statistics: Spectria T Coat-A-Count T 0.792
 0.64 nmol/liter, r  0.956, means 2.3 nmol/liter by Spectria, and
2.2 nmol/liter by Coat-A-Count.
The free T concentration was calculated from total T and SHBG
concentrations, assuming a serum albumin concentration of 43 g/liter,
and taking a value of 1  109 liters/mol for the association constant of
SHBG for total T and a value of 3.6  104 liters/mol for that of albumin
for total T (28). Insulin resistance in the fasting state was estimated from
glucose and insulin levels using the fasting insulin resistance index
(FIRI) [FIRI glucose (millimoles/liter) insulin (milliunits/liter)/25]
(29).
DNA extraction and genotype analysis
Genomic DNA was extracted from leukocytes obtained from whole-
blood samples, using commercial DNA purification kits (Wizard
Genomic DNA purification kit, Promega Corp., Madison, WI, and Nu-
cleon BAC C3, Amersham Pharmacia, Buckinghamshire, UK). Genomic
variants in TNFRSF1B were numbered on the basis of their location in
the TNFR2 mRNA sequence of GenBank accession number M32315. The
3 untranslated region (UTR) (exon 10) variants 1663 G3A, 1668 T3G,
and 1690 T3C (30) were identified by direct sequencing after PCR
amplification.
The CA repeat in intron 4 was identified by capillary electrophoresis
of PCR products using fluorescein-labeled primers (17) using an ABI310
genetic analyzer (Applied Biosystems, Foster City, CA). Four alleles of
267, 269, 271, and 273 bp were identified and termed CA13, CA14, CA15,
and CA16, reflecting the number of CA repeats (31).
The M196R (676 T3G) variant in exon 6 was detected by PCR-
restriction fragments length polymorphism analysis (16) using NlaIII
restriction enzyme. The G allele was not cut by NlaIII and appeared as
a single band (344 bp) in agarose Tris-borate-EDTA gels, whereas the T
allele was cut and appeared as two bands (235 and 109 bp).
Statistical analysis
Data are represented as mean  sd unless otherwise stated. The
Kolmogorov-Smirnov statistic, with a Lilliefors significance level for
testing normality, was applied to continuous variables. Logarithmic or
square root transformations were applied as needed to ensure normal
distribution of the variables. The influence of the TNFRSF1B genotype
and patient or control status, on sTNFR2 levels, was evaluated using a
full-factorial general linear model. Because previous reports indicate the
influence of obesity (15) and age (16) on serum sTNFR2 levels, BMI, and
age were included in the model as covariates. Unpaired t test, or one-way
ANOVA followed by the least significant difference test for post hoc
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multiple mean comparisons, was used to compare the central tendencies
of the different groups. To evaluate the association between discontin-
uous variables, we used the 2 test. Because our alternate hypothesis was
that certain alleles of the TNFRSF1B variants studied here (previously
known to increase sTNFR2 levels) were associated with hyperandro-
genism, one-tailed 2 tests were used. The difference in the proportions
among the groups and the 90% confidence interval (CI) of this difference
were calculated. The 90% confidence limits used here are consistent with
a one-tailed test using 0.05 (32). Power analysis was performed using
the G*Power software. An  value of 0.05 was chosen as the level of
significance.
Results
Serum sTNFR2 levels
A full-factorial univariate general linear model was used
to evaluate the influence on sTNFR2 levels of the different
TNFRSF1B polymorphisms and patient or control status,
introducing age and BMI as covariates. For this analysis, only
subjects in whom all the polymorphisms had been studied
were included. Therefore, the analysis included 76 patients
and 30 controls from the Spanish sample. Because one pre-
vious study has shown that big (CA15/CA16) alleles of the
CA-repeat polymorphism in intron 4 are associated with
decreased sTNFR2 levels, compared with small (CA13/
CA14) alleles (17), this polymorphism was analyzed after
assigning the subjects to three different groups: subjects hav-
ing two small alleles, subjects having two big alleles, and
subjects carrying big and small alleles.
The model was statistically significant (R2  0.962, F 
34.22, P  0.0001), and showed that only the interaction
between the 1663 G3A and the 1668 T3G variants in the
3-UTR of TNFRSF1B (P 0.05) induced changes in sTNFR2
concentrations, whereas patient or control status, the CA-
repeat polymorphism in intron 4, the M196R polymorphism
in exon 6, or any other interaction between these variables,
did not influence sTNFR2 levels significantly (data not
shown). The presence of a G allele at 1668 resulted in a
marked increase in sTNFR2 levels in subjects homozygous
for A alleles at 1663, compared with carriers of G alleles at
this position (Table 1).
The only statistically significant covariant in the model
was the BMI (P  0.019), whereas age was not significant.
Accordingly, serum sTNFR2 levels were higher in obese
subjects (BMI 	25 kg/m2), compared with lean individuals
(2226  560 vs. 1890  464 pg/ml, respectively, P  0.005),
but no correlation was observed between age and sTNFR2
levels (r  0.038, P  0.638).
Association of TNFRSF1B genotypes and
hyperandrogenism
Initial studies included 103 hyperandrogenic patients (42
of them presenting with PCOS) and 36 controls from Spain,
although some of the subjects were not included in all the
molecular genetic analyses because of DNA exhaustion.
The 3-UTR (exon 10) variants 1663 G3A, 1668 T3G, and
1690 T3C were not associated with hyperandrogenism (Ta-
ble 2). The M196R variant and the CA-repeat microsatellite
polymorphism in intron 4 of TNFRSF1B were in strong but
not complete linkage disequilibrium: CA13/CA14 alleles
were linked to 196R alleles, and CA15/CA16 alleles were
linked to 196M alleles (2  170, P  0.00001).
The sTNFR2 levels have been reported to be increased in
obesity and to correlate with indexes of insulin resistance
(11–14), conditions frequently associated with hyperandro-
genism. Because a previous study associated the CA15/
CA16/196M genotype with decreased serum sTNFR2 levels
(17), our hypothesis was a possible association of the CA13/
CA14 and 196R alleles with increased sTNFR2, hyperandro-
genism, and insulin resistance. As stated above, neither 196R
alleles nor the CA-repeat microsatellite polymorphism in
intron 4 of TNFRSF1B influenced sTNFR2 levels, and we did
not find association of any CA allele with hyperandrogenism
(data not shown). However, 196R alleles appeared to be
associated with hyperandrogenism and PCOS.
Hyperandrogenic patients presented with a 25.3% of 196R
alleles, compared with 15.3% in controls (difference in pro-
portion 10%, CI:0.5–18.1%, 2  2.994, P 0.056). Because
this result was close to statistical significance, we calculated
the statistical power of the analysis, which was 0.41, meaning
a 59% probability of excluding an association that was ac-
tually present in the population studied because of the small
sample size (type 2 error).
TABLE 2. Single nucleotide polymorphisms in the 3-UTR of
TNFRSF1B and hyperandrogenism
Patients n (%) Controls n (%) 2 P
1663 G3A GG 10 (27.8) 25 (26.3) 0.762 0.683
GA 15 (41.7) 47 (49.5)
AA 11 (30.6) 23 (24.2)
1668 T3G TT 31 (86.1) 80 (85.1) 0.021 1.000a
TG 5 (13.9) 14 (14.6)
1690 T3C TT 20 (55.6) 49 (52.1) 3.398 0.183
TC 10 (27.8) 38 (40.4)
CC 6 (16.7) 7 (7.4)
a Fisher’s exact test was used to calculate statistical significance
for 2  2 tables.
TABLE 1. Effect of the 1663 G 3 A and 1668 T 3 G variants in the 3-UTR of TNFRSF1B on serum sTNFR2 concentrations (picograms
per milliliter) in 76 patients and 30 controls from Spain considered as a whole
TNFRSF1B alleles T1668T T1668G Total
G1663G 2162  458 (32) (0) 2162  458 (32)
G1663A 2022  501 (45) 1564  238 (5) 1975  499 (50)
A1663A 2111  606 (15) 2460  980 (9) 2242  766 (24)
Total 2085  503 (92) 2140  898 (14) 2092  565 (106)
Data are means  SD. Values in parentheses indicate the number of subjects. According to the general linear model, the interaction between
the 1663 G3A and 1668 T3G variants in the 3-UTR of TNFRSF1B on sTNFR2 levels was significant with P  0.049. On the contrary, the
1663 G3A (P  0.246) and 1668 T3G (P  0.729) variants did not influence sTNFR2 levels independently.
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To increase the statistical power, we extended the analysis
by including another 11 patients from Spain and 64 patients
and 29 controls from Italy, confirming the association be-
tween 196R alleles of TNFRSF1B and hyperandrogenic dis-
orders: Considering overall allele frequencies, hyperandro-
genic patients presented with a 25.6% of 196R alleles,
compared with 17.7% in controls (difference in proportions
7.9%, CI: 2–14.5%, 2  3.274, P  0.044). Furthermore, con-
sidering the genotype distribution 44.8% of hyperandrogenic
patients were homo- or heterozygous for 196R alleles, com-
pared with only 30.8% of controls (difference in proportions
14.0%, CI: 1.2–25.5%, 2  3.823, P  0.034).
Finally, scanning for other mutations in exon 6 did not
reveal other abnormalities.
Association of TNFRSF1B genotypes in the subgroup of
PCOS patients
At present, there is substantial ongoing debate regarding
the most appropriate phenotype to study the possible influ-
ence of genetic factors in the pathogenesis of hyperandro-
genic disorders, considering the heterogeneity of this con-
dition. Because reputed authors in the field suggest that
PCOS may be a separate entity in terms of inheritance, we
have studied separately the distribution of TNFRSF1B alleles
in the subgroup of patients with PCOS diagnosis, compared
with the healthy controls.
Considering overall allele frequencies for the M196R vari-
ant, in the initial study including only Spanish patients,
women presenting with PCOS carried 196R alleles more fre-
quently than control women (30.3% in PCOS vs. 15.3% in
controls, difference in proportions 15.0%, CI: 2.3–25.9%, 2
4.692, P  0.024). This result was confirmed in the extended
study that also included Italian patients because 196R alleles
were carried by 28.4% of PCOS patients, compared with
17.7% of healthy controls (difference in proportions 10.7%,
CI: 2.2–18.2%, 2  4.960, P  0.017). Moreover, considering
the genotype distribution 48.1% of PCOS patients were ho-
mo- or heterozygous for 196R alleles, compared with only
30.8% of controls (difference in proportions 17.3%, CI: 3.3–
30.2%, 2  4.938, P  0.019).
Lack of influence of TNFRSF1B on clinical and
biochemical characteristics
Patients were younger than controls, but both groups were
matched for BMI (Table 3). Patients presented with increased
hirsutism scores, serum total T, and free T, A, DHEAS, and
insulin levels, whereas SHBG and fasting glucose were de-
creased, compared with controls (Table 3). The FIRI tended
to be higher in patients than in controls (Table 3), reaching
statistical significance when restricting the analysis to PCOS
patients (2.73  1.98 in PCOS patients vs. 2.08  1.29 in
controls, t  2.525, P  0.02).
Because the M196R variant was associated with hyperan-
drogenism and PCOS and to avoid ascertainment bias fa-
voring higher androgen levels in carriers of 196R alleles, the
possible influence of the M196R variant on clinical and bio-
chemical variables was studied separately in the control
group and patients. No differences were observed in any of
the variables studied (Table 4).
Finally, neither the CA-repeat polymorphism in intron 4
nor any of the three variants in the 3-UTR of TNFRSF1B
studied here influenced any of the clinical and biochemical
characteristics mentioned above, including BMI and the FIRI
(data not shown).
Discussion
Hyperandrogenism and PCOS are complex disorders in
terms of inheritance, suggesting that multiple genes are in-
volved in their pathogenesis. Several genes, including those
encoding for steroidogenic enzymes and genes related to
insulin secretion and action, have been proposed to play a
role in the pathogenesis of PCOS and hyperandrogenism (33,
34). However, the search for contributing genes continues,
especially because some of these associations have not been
widely confirmed by later studies (24–26).
The relationship between hyperandrogenism and disor-
ders of glucose tolerance is clearly established (6). The eti-
ologic link between these conditions seems to be insulin
resistance, which results in hyperinsulinemia and insulin-
mediated stimulation of ovarian, and possibly adrenal, an-
drogen secretion (6, 35, 36).
Recently, inflammatory cytokines such as TNF have been
TABLE 3. Clinical and biochemical characteristic of hyperandrogenic patients and controls from Spain and Italy
Hyperandrogenic
patients (n  178)
Healthy controls
(n  65)a P
Age (yr) 23.5  6.5 28.6  7.4 0.0001
BMI (kg/m2) 26.6  7.1 27.5  7.8 0.389
Hirsutism scoreb 14.2  5.6 1.5  1.5 0.0001
Total testosterone (nmol/liter) 2.2  1.0 1.4  0.5 0.0001
SHBG (nmol/liter) 36  20 54  27 0.0001
Free T (pmol/liter) 43  28 19  8.0 0.0001
A (nmol/liter) 13.0  4.7 8.7  3.1 0.0001
DHEAS (mol/liter) 7.5  3.8 5.1  2.4 0.0001
Fasting insulin (pmol/liter) 95  56 75  42 0.001
Fasting glucose (nmol/liter) 4.5  0.5 4.7  0.6 0.05
FIRI (mmol  mU  liter2) 2.53  1.68 2.07  1.29 0.076
Data are means  SD. Comparisons were made by the unpaired t test. The homogeneity of the variances was evaluated by the Levene’s test,
and the results of the t tests were interpreted accordingly.
a In 11 controls from Italian origin, serum samples were not available.
b Hirsutism scores were available for 154 patients and 36 controls, because in some patients and controls scores less than 5 were not recorded.
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proposed to play a role in the pathogenesis of insulin resis-
tance and related disorders (1). Certain high cytokine re-
sponder genotypes may have been selected during evolution
because these genotypes provide survival advantage (1): 1)
High cytokine levels facilitate defense against injury and
infection; and 2) by preserving glucose for brain metabolism,
insulin resistance could provide survival advantage against
starvation during evolution, overcoming the possible incon-
veniences of atherosclerosis and glucose intolerance, which
may appear with prolonged life expectancy of affected sub-
jects, especially when these subjects are exposed to high
carbohydrate and saturated fat contents, low-fiber diets, and
sedentary habits.
Hyperandrogenism may also represent survival advan-
tage and might also result from these high cytokine re-
sponder genotypes. The rapid maturation of the reproduc-
tive axis found in hyperandrogenic women, together with
the increase in assertive behavior resulting from increased
androgen secretion, might be advantageous during times of
environmental stress (37–39). Also, the relative infertility of
these women could increase the interval between pregnan-
cies, decreasing the birth rate, and favoring maternal and
infant survival (37). The possible involvement of high cyto-
kine responder genotypes in hyperandrogenism is sup-
ported by the recent finding of increased levels of C-reactive
protein in women with PCOS, indicating that low-grade
chronic inflammation may underlay this disorder (40).
On the basis of these considerations, we recently decided
to evaluate the possible role of the TNF system in the
pathogenesis of hyperandrogenism, and our results sug-
gested that TNF may be a contributing factor to the patho-
genesis of hyperandrogenism (7).
To further explore the TNF system, in the present study,
we have evaluated the involvement of the TNFR2 in hy-
perandrogenism. TNFR2 apparently mediates most of the
metabolic actions of TNF (41) and TNFup-regulates mark-
edly TNFR2 mRNA (42). Upon activation of TNFR2 by
TNF, sTNFR2 is shed into the circulation, modulating TNF
in a bimodal fashion depending on sTNFR2 levels: At low
concentrations sTNFR2 preserves TNF, increasing long-
term effects, whereas at high concentrations sTNFR2 neu-
tralizes TNF (43). Because TNFR2 mediates TNF actions
and sTNFR2 acts as a modulator, TNFRSF1B can be consid-
ered as a candidate gene to explain TNF-related disorders,
including insulin resistance and the metabolic syndrome.
TNFRSF1B has been studied in several metabolic disor-
ders. The 1690T3C variant has been described to influence
BMI and insulin resistance (18), the CA-repeat/M196R poly-
morphisms influence serum lipid levels (16, 17, 31) and di-
astolic blood pressure (16), and linkage studies suggest that
the TNFRSF1B locus is associated with hypertension (16) and
familial combined hyperlipidemia (17). Moreover, the CA-
repeat polymorphism has been recently proposed as a con-
tributing factor to coronary artery disease (19).
Our present results suggest that the M196R polymorphism
(which is in strong linkage disequilibrium with the CA-
repeat polymorphism) is associated with hyperandrogenism
because the frequency of carriers of the uncommon 196R
allele was increased in hyperandrogenic patients, compared
with healthy women. This association was stronger when
restricting the analysis to the subset of women presenting
with PCOS. Interestingly, consistent findings were obtained
when considering as a whole two different population sam-
ples from Spain and northeastern Italy, suggesting that the
association of the M196R polymorphism with hyperandro-
genism is not limited to Spanish women. However, our
present results do not provide any insight on the mechanism
underlying this association, as occurred with previous stud-
ies regarding TNFRSF1B in other insulin-resistant disorders
(16–19, 31).
At present there are very few data on the consequences of
the M196R variant on TNFR2 function; therefore, the asso-
ciation with hyperandrogenism and PCOS should be con-
sidered with caution. Apparently, the M196R polymorphism
does not result in significant conformational changes in the
protein or in the expression of TNFRSF1B (44), despite the
TABLE 4. Influence of the M196R (676 T 3 G) polymorphism on clinical and biochemical variables in healthy controls and
hyperandrogenic women, from Spain and Italya
TNFRSF1B alleles
Healthy controls Whole group of hyperandrogenicpatients Subgroup of PCOS patients
M196M
(n  45)
M196R and
R196R (n  20)
M196M
(n  95)
M196R and
R196R (n  77)
M196M
(n  54)
M196R and
R196R (n  50)
Age (yr) 28.4  7.3 29.5  7.8 22.8  6.1 24.3  6.8 22.8  5.5 24.0  6.4
BMI (kg/m2) 27.9  8.2 26.8  7.4 26.0  6.3 27.2  7.9 26.0  6.6 27.3  7.4
Hirsutism scoreb 1.6  1.7 1.4  1.2 14.4  5.7 14.0  5.6 13.6  5.7 13.4  6.0
Total testosterone (nmol/liter) 1.3  0.5 1.4  0.5 2.2  1.1 2.2  0.9 2.2  1.3 2.3  1.0
SHBG (nmol/liter) 52  25 49  17 35  21 36  19 34  21 32  13
Free T (pmol/liter) 19  8 20  8 44  33 41  21 46  39 44  21
A (nmol/liter) 8.7  3.1 9.1  2.4 11.0  4.4 13.7  5.1 12.5  4.5 14.0  4.5
DHEAS (mol/liter) 4.7  2.2 6.0  2.8 7.9  4.1 7.1  3.4 7.2  3.6 7.0  3.4
Fasting insulin (pmol/liter) 77  45 66  31 94  60 97  54 102  73 103  61
Fasting glucose (nmol/liter) 4.7  0.6 4.8  0.7 4.5  0.6 4.5  0.5 4.5  0.6 4.5  0.5
FIRI (mmol  mU  liter2) 2.11  1.38 1.90  1.07 2.50  1.78 2.57  1.60 2.72  2.1 2.75  1.81
Data are means  SD. Patients and controls were analyzed separately. No significant differences between genotypes were found using
unpaired t test. The homogeneity of the variances was evaluated by the Levene’s test, and the results of the t tests were interpreted accordingly.
a In 11 controls from Italian origin, serum samples were not available.
b Hirsutism scores were available for 26 controls and 85 patients presenting with the M196M genotype, and in 10 controls and 63 patients
presenting with the M196R or R196R genotype, because in 29 controls and 25 PCOS patients scores below 5 were not recorded.
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fact that exon 6 encodes the proteolytic site that mediates
shedding of sTNFR2. However, because of the complex func-
tional interdependency among TNF, TNFR2, and sTNFR2,
the possibility that minor changes in TNFR2 structure or
function induced by the M196R variant might influence
TNF actions in vivo exists.
Both the M196R variant in exon 6 and the CA-repeat poly-
morphism in intron 4 of TNFRSF1B have been shown to
influence shedding of TNFR2 in two previous studies (16,
17), although the results were not completely concordant. In
our present study, however, the only genotypic effect of
TNFRSF1B on sTNFR2 levels is an interaction between the
1663 G3A and the 1668 T3G variants, but no effect of the
M196R variant and the CA-repeat polymorphism on sTNFR2
levels was found. This discrepancy with the previous studies
cited above (16, 17) might be due to the peculiar character-
istics of subjects we studied (i.e. hyperandrogenic women).
Alternatively, it could depend on the different statistical
approach used in our study. The use of a more strict general
linear model allowed us to correct for age and obesity, avoid-
ing the confounding interference of these factors on the pos-
sible influence of the TNFRSF1B genotype, and patient or
control status, on sTNFR2 levels. In addition to avoiding
spurious associations, this approach allowed us to explore
precisely the interaction among the different genomic variants
described here, between them and with hyperandrogenism.
However, the association between 196R alleles and hy-
perandrogenism should be weighted carefully because
carriers of this variant did not present with increased
serum androgens, hirsutism score, BMI, or markers of
insulin resistance, compared with subjects homozygous
for 196M alleles. This finding suggests that the TNFRSF1B
genotype might be a contributing factor in the pathogen-
esis of hyperandrogenism by a hypothetical facilitation of
TNF actions (7), but there exists the possibility that the
M196R variant is in linkage disequilibrium with yet un-
known mutation, which is the actual contributor to hy-
perandrogenism, as suggested for familial combined hy-
perlipidemia by others (17).
As stated above, carriers of308A TNF alleles presented
with higher androgen levels, compared with wild-type al-
leles (7). Interestingly, we have not found any association
between the 196R alleles of TNFRSF1B and 308A alleles of
the TNF gene in 79 subjects who had been previously geno-
typed for the TNF G-308A variant (2  0.202, P  0.904),
ruling out any significant cooperative effect of these genomic
variants on the pathogenesis of androgen excess.
In summary, our present results suggest that the
TNFRSF1B genotype might influence hyperandrogenism
and PCOS, further supporting the contribution of inflam-
matory cytokines to the pathogenesis of these disorders.
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